Literature DB >> 26780294

Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.

Pamela N Peters1, Elizabeth M Schryver1, Ernst Lengyel1, Hilary Kenny2.   

Abstract

The pattern of ovarian cancer metastasis is markedly different from that of most other epithelial tumors, because it rarely spreads hematogenously. Instead, ovarian cancer cells exfoliated from the primary tumor are carried by peritoneal fluid to metastatic sites within the peritoneal cavity. These sites, most notably the abdominal peritoneum and omentum, are organs covered by a mesothelium-lined surface. To investigate the processes of ovarian cancer dissemination, we assembled a complex three-dimensional culture system that reconstructs the lining of the peritoneal cavity in vitro. Primary human fibroblasts and mesothelial cells were isolated from human omentum. The fibroblasts were then mixed with extracellular matrix and covered with a layer of the primary human mesothelial cells to mimic the peritoneal and omental surfaces encountered by metastasizing ovarian cancer cells. The resulting organotypic model is, as shown, used to examine the early steps of ovarian cancer dissemination, including cancer cell adhesion, invasion, and proliferation. This model has been used in a number of studies to investigate the role of the microenvironment (cellular and acellular) in early ovarian cancer dissemination. It has also been successfully adapted to high throughput screening and used to identify and test inhibitors of ovarian cancer metastasis.

Entities:  

Mesh:

Year:  2015        PMID: 26780294      PMCID: PMC4780905          DOI: 10.3791/53541

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  31 in total

1.  Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models.

Authors:  T Kishikawa; M Sakamoto; Y Ino; K Kubushiro; S Nozawa; S Hirohashi
Journal:  Invasion Metastasis       Date:  1995

2.  Mesothelial cells induce the motility of human ovarian carcinoma cells.

Authors:  M Rieppi; V Vergani; C Gatto; G Zanetta; P Allavena; G Taraboletti; R Giavazzi
Journal:  Int J Cancer       Date:  1999-01-18       Impact factor: 7.396

3.  In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.

Authors:  T Strobel; L Swanson; S A Cannistra
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

4.  Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro.

Authors:  T Strobel; S A Cannistra
Journal:  Gynecol Oncol       Date:  1999-06       Impact factor: 5.482

5.  Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment.

Authors:  Nuzhat Ahmed; Clyde Riley; Greg Rice; Michael Quinn
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

6.  CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells.

Authors:  K Lessan; D J Aguiar; T Oegema; L Siebenson; A P Skubitz
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

7.  Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression.

Authors:  Maria V Barbolina; Brian P Adley; Edgardo V Ariztia; Yueying Liu; M Sharon Stack
Journal:  J Biol Chem       Date:  2006-12-11       Impact factor: 5.157

Review 8.  Pathology of the peritoneum: a review of selected topics.

Authors:  D Daya; W T McCaughey
Journal:  Semin Diagn Pathol       Date:  1991-11       Impact factor: 3.464

9.  In vitro degradation of extracellular matrix by human ovarian carcinoma cells.

Authors:  M J Niedbala; K Crickard; R J Bernacki
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

10.  Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.

Authors:  Kathryn M Burleson; Rachael C Casey; Keith M Skubitz; Stephan E Pambuccian; Theodore R Oegema; Amy P N Skubitz
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

View more
  6 in total

1.  Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.

Authors:  Sean McGuire; Betul Kara; Peter C Hart; Anthony Montag; Kristen Wroblewski; Sarah Fazal; Xin-Yun Huang; Ernst Lengyel; Hilary A Kenny
Journal:  Gynecol Oncol       Date:  2019-02-20       Impact factor: 5.482

2.  Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis.

Authors:  Suchitra Natarajan; Kaitlyn M Foreman; Michaela I Soriano; Ninna S Rossen; Hussein Shehade; Daniel R Fregoso; Joshua T Eggold; Venkatesh Krishnan; Oliver Dorigo; Adam J Krieg; Sarah C Heilshorn; Subarna Sinha; Katherine C Fuh; Erinn B Rankin
Journal:  Cancer Res       Date:  2019-03-12       Impact factor: 12.701

Review 3.  Organotypic 3D Models of the Ovarian Cancer Tumor Microenvironment.

Authors:  Karen M Watters; Preety Bajwa; Hilary A Kenny
Journal:  Cancers (Basel)       Date:  2018-08-09       Impact factor: 6.639

4.  Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression.

Authors:  Sumegha Mitra; Kartikeya Tiwari; Ram Podicheti; Taruni Pandhiri; Douglas B Rusch; Andrea Bonetto; Chi Zhang; Anirban K Mitra
Journal:  Cancers (Basel)       Date:  2019-10-09       Impact factor: 6.639

Review 5.  Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine.

Authors:  Christine Yee; Kristie-Ann Dickson; Mohammed N Muntasir; Yue Ma; Deborah J Marsh
Journal:  Front Bioeng Biotechnol       Date:  2022-02-10

6.  Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis.

Authors:  Claire Henry; Neville Hacker; Caroline Ford
Journal:  Oncotarget       Date:  2017-11-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.